PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-Driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery
OXFORD, England and TORONTO – (BUSINESS WIRE) – PrecisionLife Ltd. (“PrecisionLife”), the leading combinatorial analysis company promoting understanding of disease biology and patient stratification, and Cyclica Inc. (“Cyclica”), the partner of choice for evidence-based drug discovery. data, announce that they have entered into a strategic partnership to co-market and deliver their complementary IT platforms as an integrated drug discovery factory. The companies will initially collaborate on up to 30 pharmaceutical and biotechnology drug discovery programs over the next two years.
Together, the two companies have the capacity to advance a large number of innovative AI-enhanced drug discovery programs and build an industrial portfolio of partnered R&D opportunities. The agreement is fueled by 17 chronic disease studies that PrecisionLife completed last year, which revealed detailed patient stratifications and multiple new drug targets by disease, as well as Cyclica’s existing strategic relationships with several academic partners. , biotechnology and pharmaceuticals, which has resulted in a portfolio of several joint ventures in several therapeutic areas. The companies each have multiple ongoing business partnership discussions with biotech and pharmaceutical companies.
The PrecisionLife Platform has been proven to generate more information from patient datasets, identifying multiple disease mechanisms, with new drug targets, patient stratification biomarkers and chemical starting points, by particularly around unmet medical needs in chronic diseases. Cyclica’s platform uses a proteome-scale lens to simultaneously assess several new and rare interactions on and off target. Cyclica’s multi-objective drug design approach and lead optimization cycles are among the most efficient in the industry, allowing new molecules to be designed, synthesized and tested in a matter of weeks.
“Finding the right target and understanding which patients will benefit from it is the major challenge of modern drug discovery.” said Naheed Kurji, President and CEO of Cyclica. âCyclica is building one of the largest and most diverse portfolios of drug discovery programs in therapeutically rich and diverse areas. PrecisionLife’s detailed and innovative knowledge of the biology of complex diseases and relevant targets for which patient subgroups provides a major advantage as we build the biotechnology pipeline of the future.
“Cyclica’s high-quality platform, team and business model are a key part of our strategy to find new therapeutic approaches for unmet medical needs.” said Steve Gardner, CEO of PrecisionLife. âTogether, we are building a new pipeline based on world-leading AI-powered biology and chemistry that will deliver new drugs to patients faster and more precisely in a wide variety of therapeutic areas.â
PrecisionLife is headquartered near Oxford, UK, and has operations in Aalborg and Copenhagen, Denmark, Warsaw, Poland and Cambridge, Massachusetts, USA. The company’s unique combinatorial analytics platform generates more insight into the complex biology of chronic disease, propelling the next wave of precision medicine applications and finding new treatment opportunities for unmet medical needs of patients. PrecisionLife partners with charities, clinical research groups, CROs, leading technology providers, and pharmaceutical, biotechnology and healthcare companies to improve our knowledge of the biology of chronic disease. PrecisionLife harnesses an innovation engine that translates proprietary knowledge of disease biology into new drug discovery programs, more successful and cost-effective clinical trials, and more personalized clinical decision support tools.
For more information, see https://precisionlife.com/
Follow us on LinkedIn (precisionlife) and Twitter (@precisionlifeAI)
From molecules to medicine, Cyclica embraces the complexity of disease. With deep roots in the industry, a world-class platform and an innovative decentralized partnership model, Cyclica creates drugs with greater precision for unmet patient needs. Our work encompasses dozens of collaborations with major pharmaceutical and biotechnology companies as well as several joint ventures. We are a passionate team of biotechnology and pharma professionals, biologists, chemists and computer scientists who live and work at the intersection of our collective expertise. To learn more about Cyclica and our partnership, please visit www.cyclicarx.com
This press release contains forward-looking statements and forward-looking information which include, among other things, the ability to progress and the number of drug discovery programs to be undertaken by PrecisionLife and Cyclica in accordance with the Partnership. These statements and information are based on management’s beliefs and assumptions and on information currently available to management, and involve risks, uncertainties and other factors that could cause performance or achievement to differ materially. actual results and those expressed or implied by these forward-looking statements. and information. While we believe that we have a reasonable basis for each forward-looking statement and forward-looking information contained in this press release, we caution you that such statements are based on a combination of facts and factors currently known to us and our projections for the future. , of which we cannot be certain. We cannot assure you that the forward-looking statements and forward-looking information contained in this press release will prove to be correct.